TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late […]
Coronary/Structural Heart
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara’s new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage […]
Ancora Heart AccuCinch® System Shows Positive 12-Month Outcomes in Multi-Study Analysis
Results Presented at Transcatheter Cardiovascular Therapeutics 2021 ORLANDO, Fla.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced results from an analysis of multiple studies that showed positive outcomes with its investigational AccuCinch® Ventricular Restoration System. The results were presented during a Featured Clinical Research […]
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
– In a new sub-analysis of the landmark EMPEROR-Preserved® Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 – Empagliflozin consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m2 1 INGELHEIM, […]
egnite, Inc. Presented New Data on the Use of Artificial Intelligence to Predict the Progression of Aortic Stenosis at TCT 2021 Conference
AI-powered algorithms are proven to accurately predict the likelihood a patient with moderate AS has progressed to severe AS. ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc. presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 conference held November 4-6. The presentation showcased the proven accuracy and results of artificial intelligence (AI) […]
Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy
New Data at TCT From the Disrupt CAD Clinical Program Demonstrate Consistency of Shockwave IVL Outcomes Over Time, Across Calcium Morphologies and Between Genders November 05, 2021 08:00 ET | Source: Shockwave Medical, Inc. SANTA CLARA, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the […]
Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint
WINNIPEG, MB, Nov. 4, 2021 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the results from the SAVI-PCI clinical trial demonstrating that the use of short infusion AGGRASTAT® (tirofiban hydrochloride) injection was non-inferior to label-dosing INTEGRILIN® (eptifibatide) or long-infusion AGGRASTAT® in a primary […]
TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis
IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This analysis from the PARTNER 3 trial was presented during the […]
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure
November 05, 2021 08:00 ET | Source: Orchestra BioMed BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation. Patients with Isolated Systolic Hypertension (ISH) treated with BackBeat CNT experienced clinically meaningful and statistically significant reductions of 7.4 mmHg in ambulatory systolic […]
Stamford Health Forges New Relationship with Columbia University Irving Medical Center to Expand World-Class Heart Surgery Capabilities
STAMFORD, CT/ NOVEMBER 3, 2021— Stamford Health, known for its award-winning cardiac care through the Heart & Vascular Institute, has expanded its relationship with Columbia University to offer treatment and expertise from Columbia University Irving Medical Center’s nationally recognized heart surgeons. As a result of this new relationship, five of […]



